Investigating Novel Strategies for the Treatment of Metastatic Small Cell Lung Cancer After Frontline Treatment Failure

This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2023.

Program Description

Small cell lung cancer (SCLC) is an aggressive cancer that is often diagnosed in advanced stages due to its rapid tumor growth and early metastases. Patients with SCLC often develop resistance quickly and, historically, second-line treatment has been limited. Novel agents including several under investigation for patients with SCLC who relapse or are refractory to platinum-based frontline treatment have the potential to address these challenges. The discussion will center on strategies for oncology pharmacists to optimize the use of second-line therapies including lurbinectedin and topotecan for patients with extensive-stage SCLC. Although the safety profile of second-line agents is generally manageable, they have been associated with several clinically significant adverse effects that oncology pharmacists should be aware of and equipped to manage. This program will feature patient case discussions focusing on individualizing care in advanced SCLC, optimizing dosing and administration, and monitoring for and managing adverse effects.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: April 27, 2023
Expiration date: April 27, 2024

Time to complete activity: 1.0 hour

Learner level: Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify important pharmacologic parameters that patients and health care practitioners should be aware of prior to initiation of novel agents in the second-line treatment of extensive-stage small cell lung cancer (ES-SCLC)
• Apply novel second-line treatment strategies into regimens in ES-SCLC
• Demonstrate strategies for the management of treatment-related toxicities in real-world scenarios in ES-SCLC

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-23-195-H01-P. The activity is available for CE credit through April 27, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Chung-Shien Lee, PharmD, BCPS, BCOP, and Shelby Merchant, PharmD, BCOP, have no relevant financial relationships with commercial interests to disclose.

Amanda S. Cass, PharmD, BCPS, BCOP, has the following relevant financial relationships with commercial interests to disclose: 

Consultant: G1 Therapeutics, Takeda

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA, CHCP; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.


Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms